PURPOSE: We investigate the efficacy of 0.03% topical tacrolimus eyedrops for the treatment of dry eye in graft versus host disease (GVHD) patients resistant/intolerant to 0.05% topical cyclosporine. METHODS: Forty-three patients were enrolled in this prospective study. After completing a 1-year run-in period of using artificial tears, 50% autologous serum eyedrops, and punctal plug occlusion, all the symptomatic patients (n=29) were treated with 0.05% topical cyclosporine (Restasis(®); Allergan, Inc.). After 1 month, the patients who presented topical or systemic intolerance to cyclosporine were instructed to instill 0.03% topical tacrolimus once a day for 3 months (n=14). All the patients were allowed to continue with their basal dry eye treatment. Visual acuity, fluorescein staining, Schirmer test, fluorescein tear break-up time, and tear meniscus height measurement were evaluated fortnightly (minimum 3 months). Subjective assessments of symptoms were also reported at the beginning and at the end of the study. RESULTS: Dry eye symptoms and signs improved statistically (P<0.05) and significantly with tacrolimus and cyclosporine topical treatment. No significant differences were observed between both the groups. The mean follow-up time was 12.14±2.69 months (range 10-18 months). CONCLUSION: The findings of this prospective pilot study suggest that cyclosporine-intolerant patients with dry eye associated with GVHD can be effectively treated with topical tacrolimus.
PURPOSE: We investigate the efficacy of 0.03% topical tacrolimus eyedrops for the treatment of dry eye in graft versus host disease (GVHD) patients resistant/intolerant to 0.05% topical cyclosporine. METHODS: Forty-three patients were enrolled in this prospective study. After completing a 1-year run-in period of using artificial tears, 50% autologous serum eyedrops, and punctal plug occlusion, all the symptomatic patients (n=29) were treated with 0.05% topical cyclosporine (Restasis(®); Allergan, Inc.). After 1 month, the patients who presented topical or systemic intolerance to cyclosporine were instructed to instill 0.03% topical tacrolimus once a day for 3 months (n=14). All the patients were allowed to continue with their basal dry eye treatment. Visual acuity, fluorescein staining, Schirmer test, fluorescein tear break-up time, and tear meniscus height measurement were evaluated fortnightly (minimum 3 months). Subjective assessments of symptoms were also reported at the beginning and at the end of the study. RESULTS:Dry eye symptoms and signs improved statistically (P<0.05) and significantly with tacrolimus and cyclosporine topical treatment. No significant differences were observed between both the groups. The mean follow-up time was 12.14±2.69 months (range 10-18 months). CONCLUSION: The findings of this prospective pilot study suggest that cyclosporine-intolerant patients with dry eye associated with GVHD can be effectively treated with topical tacrolimus.
Authors: J J Fung; M Eliasziw; S Todo; A Jain; A J Demetris; J P McMichael; T E Starzl; P Meier; A Donner Journal: J Am Coll Surg Date: 1996-08 Impact factor: 6.113
Authors: Y Ogawa; S Okamoto; M Wakui; R Watanabe; M Yamada; M Yoshino; M Ono; H Y Yang; Y Mashima; Y Oguchi; Y Ikeda; K Tsubota Journal: Br J Ophthalmol Date: 1999-10 Impact factor: 4.638
Authors: João Baptista Malta; H Kaz Soong; Roni M Shtein; David C Musch; William Rhoades; Alan Sugar; Shahzad I Mian Journal: Cornea Date: 2010-12 Impact factor: 2.651
Authors: Britt E Anderson; Jennifer M McNiff; Dhanpat Jain; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik Journal: Blood Date: 2004-11-02 Impact factor: 22.113
Authors: S Aronni; M Cortes; M Sacchetti; A Lambiase; A Micera; R Sgrulletta; S Bonini Journal: Eur J Ophthalmol Date: 2006 Jan-Feb Impact factor: 2.597
Authors: Daniel Couriel; Paul A Carpenter; Corey Cutler; Javier Bolaños-Meade; Nathaniel S Treister; Juan Gea-Banacloche; Paul Shaughnessy; Sharon Hymes; Stella Kim; Alan S Wayne; Jason W Chien; Joyce Neumann; Sandra Mitchell; Karen Syrjala; Carina K Moravec; Linda Abramovitz; Jerry Liebermann; Ann Berger; Lynn Gerber; Mary Schubert; Alexandra H Filipovich; Daniel Weisdorf; Mark M Schubert; Howard Shulman; Kirk Schultz; Barbara Mittelman; Steven Pavletic; Georgia B Vogelsang; Paul J Martin; Stephanie J Lee; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2006-04 Impact factor: 5.742
Authors: Tulio B Abud; Francisco Amparo; Ujwala S Saboo; Antonio Di Zazzo; Thomas H Dohlman; Joseph B Ciolino; Pedram Hamrah; Reza Dana Journal: Ophthalmology Date: 2016-04-13 Impact factor: 12.079
Authors: Aileen Sy; Kieran S O'Brien; Margaret P Liu; Puja A Cuddapah; Nisha R Acharya; Thomas M Lietman; Jennifer Rose-Nussbaumer Journal: BMC Ophthalmol Date: 2015-10-13 Impact factor: 2.209
Authors: Mihir Shah; Maria C Edman; Srikanth Reddy Janga; Frances Yarber; Zhen Meng; Wannita Klinngam; Jonathan Bushman; Tao Ma; Siyu Liu; Stan Louie; Arjun Mehta; Chuanqing Ding; J Andrew MacKay; Sarah F Hamm-Alvarez Journal: Invest Ophthalmol Vis Sci Date: 2017-01-01 Impact factor: 4.799